CU23742B7 - IVABRADINA INJECTABLE COMPOSITION - Google Patents

IVABRADINA INJECTABLE COMPOSITION

Info

Publication number
CU23742B7
CU23742B7 CU20090186A CU20090186A CU23742B7 CU 23742 B7 CU23742 B7 CU 23742B7 CU 20090186 A CU20090186 A CU 20090186A CU 20090186 A CU20090186 A CU 20090186A CU 23742 B7 CU23742 B7 CU 23742B7
Authority
CU
Cuba
Prior art keywords
ivabradina
injectable composition
sodium chloride
ivabradine hydrochloride
hydrate
Prior art date
Application number
CU20090186A
Other languages
Spanish (es)
Other versions
CU20090186A7 (en
Inventor
Carmen Fleurinck
Ariane Dubost-Brama
Guy Lerebourgs-Pigeonniere
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Priority to CU20090186A priority Critical patent/CU23742B7/en
Publication of CU20090186A7 publication Critical patent/CU20090186A7/en
Publication of CU23742B7 publication Critical patent/CU23742B7/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

la presente invención tienen por objetouna composición farmacéutica, la cual se administra por vía intravenosa que contienen como ingrediente activo clorhidrato de ivabradina o un hidrato del mismo, en combinación con cloruro de sodio como excipiente, en donde la relación cloruro de sodio/clorhidrato de ivabradina es de alrededor de 444444444,2 p/p.A subject of the present invention is a pharmaceutical composition, which is administered intravenously containing as an active ingredient ivabradine hydrochloride or a hydrate thereof, in combination with sodium chloride as an excipient, wherein the ratio sodium chloride / ivabradine hydrochloride It is around 444444444.2 p / p.

CU20090186A 2009-11-06 2009-11-06 IVABRADINA INJECTABLE COMPOSITION CU23742B7 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CU20090186A CU23742B7 (en) 2009-11-06 2009-11-06 IVABRADINA INJECTABLE COMPOSITION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20090186A CU23742B7 (en) 2009-11-06 2009-11-06 IVABRADINA INJECTABLE COMPOSITION

Publications (2)

Publication Number Publication Date
CU20090186A7 CU20090186A7 (en) 2011-10-05
CU23742B7 true CU23742B7 (en) 2011-12-28

Family

ID=45000058

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20090186A CU23742B7 (en) 2009-11-06 2009-11-06 IVABRADINA INJECTABLE COMPOSITION

Country Status (1)

Country Link
CU (1) CU23742B7 (en)

Also Published As

Publication number Publication date
CU20090186A7 (en) 2011-10-05

Similar Documents

Publication Publication Date Title
CR20120019A (en) PROLONGED INSULIN COMPOSITION
PE20200175A1 (en) SUSTAINED RELEASE RUXOLITINIB DOSAGE FORMS
CO6761298A2 (en) Combinations comprising atypical antipsychotics and taar1 antagonists
CU20080114A7 (en) INTRAVENOUS EMULSION OF BUTILFTALIDA AND APPLICATION OF THE SAME
CO6670520A2 (en) Lactmas substituted with piperidinium as modulators of gpr119
MX2015016254A (en) Tamper resistant dosage form with bimodal release profile.
BR112015017525A2 (en) modified peptide, salt of a modified peptide, medicament, and methods for treating or alleviating cardiovascular disease and for producing a modified peptide
EA201591363A1 (en) TIADIAZOLE ANALOGUES AND METHODS OF TREATMENT OF STATES ASSOCIATED WITH SMN DEFICIENCY
GT201300208A (en) NEW NOVELS DERIVED FROM CYCLIC AZABENCIMIDAZOL USEFUL AS ANTIDIABETIC AGENTS
CL2013000716A1 (en) A prodrug or a salt thereof comprising an exendin-conjugate conjugate; preparation procedure of said prodrug; intermediary compounds; pharmaceutical composition that includes it, useful to improve glycemic control in patients with type 2 diabetes.
ECSP088239A (en) COMPOSITION OF SUSTAINED DRUG RELEASE
MX369818B (en) Selective pyy compounds and uses thereof.
BR112015017451A2 (en) breach resistant pharmaceutical formulations
BR112015011430A2 (en) composition for immediate and prolonged release
CO6300965A2 (en) CONJUGATES OF BIOCOMPATIBLE POLYMERS OF FACTOR IX, COMPOSITIONS THAT INCLUDE CONJUGATES OF FACTOR IX AND, TREATMENT METHODS
NI201200189A (en) "PHARMACEUTICAL COMPOSITIONS INCLUDING 4-AMINO-5-FLUORO-3- [6- (4-METHYL-PIPERAZIN-1-IL) -1H-BENZIMIDAZOL-2-IL] -1H-QUINOLIN-2-ONA LACTATE MONOHYDRATE "
EA201300990A1 (en) PARENTAL INTRODUCTION OF TAPENTADOL
CR20110209A (en) SOLID PHARMACEUTICAL COMPOSITION
BR112016007414A2 (en) method of producing a monolayer tablet, and monolayer tablet
MX366499B (en) LIQUID PHARMACEUTICAL COMPOSITION.
MX2014014662A (en) Manufacture of degarelix.
CL2009000904A1 (en) Compounds derived from cyclohexyl sulfonamides having antagonist activity at the npy y5 receptor, pharmaceutical composition and pharmaceutical formulation comprising them.
MX363389B (en) Pharmaceutical composition comprising amorphous ivabradine.
EA201170101A1 (en) PHARMACEUTICAL COMPOSITIONS ROWVASTATINA CALCIUM
GT201500038A (en) DIFFENIDOL COMPOSITION OF PROLONGED RELEASE.

Legal Events

Date Code Title Description
FG Grant of patent